

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hidehito KOTANI, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/JP03/07534

GAU:

FILED: Herewith

EXAMINER:

FOR: METHOD FOR PREDICTING A DRUG TRANSPORT CAPABILITY BY ABCG2 POLYMORPHISMS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Corwin P. Umbach, Ph.D.
Registration No. 40,211

Registration No. 34,423

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

10/517310

PTO Rec'd 1170 DEC 3 2004

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 262507US0PCT		SERIAL NO. New U.S. PCT Application Based on PCT/JP03/07534	
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Hidehito KOTANI, et al.					
		FILING DATE Herewith		GROUP			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AO	02/28894	04/11/02	WO	YES	NO	NO
	AP	1 323 735	07/02/03	EP			NO
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	NAKATOMI, Katsumi ET AL: "Mutation and quantitative analysis of breast cancer resistance protein (BCRP/MXR/ABCG2) gene in lung cancer cells and tumor tissues" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, no. 3855, page 778, March 2002.					
	AX	HONJO, Yasumasa ET AL: "single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter MXR/BCRP/ABCP1/ABCG2" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, no. 3858, pages 778-779, March 2002.					
	AY	ALLEN, John ET AL: "A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance", CANCER RESEARCH, vol. 62, no. 8, pages 2294-2299, April 15, 2002.					
	AZ	DOYLE, L A. ET AL: "A MULTIDRUG RESISTANCE TRANSPORTER FROM HUMAN mcf-7 BREAST CANCER CELLS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE., vol. 95, pages 15665-15670, December 1998.					<input checked="" type="checkbox"/> Additional References sheet(s) attached
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 262507US0PCT	SERIAL NO. New U.S. PCT Application Based on PCT/JP03/07534
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT	Hidehito KOTANI, et al.	
		FILING DATE	GROUP Herewith	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)				
	AAA	DATABASE EMBL 'Online! EBI; "603176769F1 NIH_MGC_121 Homo sapiens cDNA clone IMAG:5240944 5" retrieved from HTTP://WWW.EBI.AC.UK, October 21, 2001.		
	AAB	HONJO, Y ET AL: "Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 61, no. 18, pages 6635-6636, September 15, 2001.		
	AAC	IMAI, Yasuo ET AL: "C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance", MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 8, pages 611-616, June 17, 2002		
	AAD	IIDA, A ET AL: "Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, ABCG8" JAPANESE JOURNAL OF HUMAN GENETICS, vol. 47, no. 6, pages 285-310, June 28, 2002.		
	AAE			
	AAF			
	AAG			
	AAH			
	AAI			
	AAJ			
	AAK			
	AAL			
	AAM			
	AAN			
	AAO			
	AAP			
	AAQ			
Examiner			Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				